title: [Evolution of adherence to guidelines for prevention of group B streptococcal infections].
abstract: OBJECTIVE
  Assess the evolution in implementation of neonatal group B streptococcal infections prevention program in the Aurore network, between 2004 and 2009.
  
  
  METHODS
  A cross-sectional study was conducted during one week in the whole maternity units of the Aurore network about implementation of the neonatal streptococcal infection prevention program. Deliveries occurring after 37 weeks of gestation were included. Every stage required by the prevention program was registered for every delivery. Results obtained during this study were compared with those obtained in 2004.
  
  
  RESULTS
  Seven hundred and forty-four patients were included in 2004 and 618 in 2009. Vaginal swab rate was 96.3% in 2009 and 91.1% in 2004 (P<0.001), with a positive rate of 10.2 and 14.2%, respectively (P=0.041). Antibiotic infusion rates during delivery did not increase significantly. Clinical and biological surveillance of exposed newborns was significantly increased (P<0.001). No neonatal infection was observed during the study among newborns included in the program.
  
  
  CONCLUSIONS
  Sensitization of caregivers about neonatal streptococcal infection prevention seems to be efficient to increase the application of the prevention program written by the Aurore network.
authors.affiliation: Service de gynécologie-obstétrique, hospices civils de Lyon, hôpital de la Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon cedex 04, France. marion.cortet@chu-lyon.fr
authors.forename: M
authors.initials: M
authors.lastname: Cortet
authors.forename: C
authors.initials: C
authors.lastname: Dupont
authors.forename: V
authors.initials: V
authors.lastname: Prunaret-Julien
authors.forename: M-P
authors.initials: MP
authors.lastname: Fernandez
authors.forename: E
authors.initials: E
authors.lastname: Peigne
authors.forename: C
authors.initials: C
authors.lastname: Huissoud
authors.forename: R-C
authors.initials: RC
authors.lastname: Rudigoz
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D036861:Delivery, Obstetric; D005260:Female; D005602:France; D005865:Gestational Age; D019983:Guideline Adherence; D006284:Health Plan Implementation; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D013290:Streptococcal Infections / Q000175:diagnosis / Q000517:prevention & control* / Q000635:transmission; D013292:Streptococcus agalactiae / Q000302:isolation & purification; D014621:Vagina / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents